FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making